Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Yield
How to Buy Corporate Bonds
How to Buy Treasury Bonds
How to Invest in Real Estate Online
Money
Compare Online Brokers
Stock Brokers
Forex Brokers
Futures Brokers
Crypto Brokers
Options Brokers
ETF Brokers
Mutual Fund Brokers
Index Fund Brokers
Bond Brokers
Short Selling Brokers
Stock Apps
All Broker Reviews
Insurance
Auto
Home
Medicare
Life
Vision
Dental
Business
Pet
Health
Motorcycle
Renters
Workers Comp
Top Stocks
Penny Stocks
Stocks Under $5
Stocks Under $10
Stocks Under $20
Stocks Under $50
Stocks Under $100
Alternative Investing
Invest in Art
Invest in Watches
Invest in Land
Invest in Real Estate
Invest in Wine
Invest in Gold
Mortgages
Refinance
Purchase
Find a Mortgage Broker
Consumer
Moving
Living
Alts
Alternative Investment Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
How to Invest in Jewelry
Best Real Estate Crowdfunding Platforms
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Get Started
Is Bitcoin a Good Investment?
Is Ethereum a Good Investment?
What is Blockchain
Best Altcoins
How to Buy Cryptocurrency?
DeFi
Crypto and DeFi 101
What is DeFi?
Decentralized Exchanges
Best DeFi Yield Farms
Digital Securities
NFTs
NFT Release Calendar
What is a Non-Fungible Token (NFT)?
How to Buy Non-Fungible Tokens (NFTs)
CryptoPunks Watchlist
Are NFTs a Scam or a Digital Bubble?
Best In Crypto
Best Crypto Apps
Best Crypto Portfolio Trackers
Best Crypto Day Trading Strategies
Best Crypto IRA
Best Cryptocurrency Scanners
Best Business Crypto Accounts
Best Crypto Screeners
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Yield
How to Buy Corporate Bonds
How to Buy Treasury Bonds
How to Invest in Real Estate Online
Money
Compare Online Brokers
Stock Brokers
Forex Brokers
Futures Brokers
Crypto Brokers
Options Brokers
ETF Brokers
Mutual Fund Brokers
Index Fund Brokers
Bond Brokers
Short Selling Brokers
Stock Apps
All Broker Reviews
Insurance
Auto
Home
Medicare
Life
Vision
Dental
Business
Pet
Health
Motorcycle
Renters
Workers Comp
Top Stocks
Penny Stocks
Stocks Under $5
Stocks Under $10
Stocks Under $20
Stocks Under $50
Stocks Under $100
Alternative Investing
Invest in Art
Invest in Watches
Invest in Land
Invest in Real Estate
Invest in Wine
Invest in Gold
Mortgages
Refinance
Purchase
Find a Mortgage Broker
Consumer
Moving
Living
Alts
Alternative Investment Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
How to Invest in Jewelry
Best Real Estate Crowdfunding Platforms
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Get Started
Is Bitcoin a Good Investment?
Is Ethereum a Good Investment?
What is Blockchain
Best Altcoins
How to Buy Cryptocurrency?
DeFi
Crypto and DeFi 101
What is DeFi?
Decentralized Exchanges
Best DeFi Yield Farms
Digital Securities
NFTs
NFT Release Calendar
What is a Non-Fungible Token (NFT)?
How to Buy Non-Fungible Tokens (NFTs)
CryptoPunks Watchlist
Are NFTs a Scam or a Digital Bubble?
Best In Crypto
Best Crypto Apps
Best Crypto Portfolio Trackers
Best Crypto Day Trading Strategies
Best Crypto IRA
Best Cryptocurrency Scanners
Best Business Crypto Accounts
Best Crypto Screeners
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Gilead Sciences
(NASDAQ:GILD)
Intraday
$73.50
0.24
[0.33%]
15 minutes delayed
GET A REPORT ON
GILD
SENT RIGHT TO YOUR INBOX
EMAIL*
Submit
Cancel
Get Report
Watch
Perks
Buy
Compare Brokers
$73.50
0.24
[0.33%]
Last update: 8:49AM
Get Real Time Here
GET A REPORT ON
GILD
SENT RIGHT TO YOUR INBOX
EMAIL*
Submit
Cancel
Get Report
Watch
The dividend Ex-Date was 5 days ago
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Gilead Sciences Stock (NASDAQ:GILD)
Gilead Sciences Stock (NASDAQ: GILD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, March 19, 2024
Gilead Helps Launch Türkiye's First HIV Testing Week
Benzinga Newsdesk
-
14 minutes ago
Friday, March 15, 2024
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
Vandana Singh
-
3 days ago
Gilead Executive Said CAR-T Cancer Therapy Capacity To Quadruple By 2026
Charles Gross
-
4 days ago
Monday, March 11, 2024
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,100 Today
Benzinga Insights
-
Mar 11, 2024, 5:30PM
Gilead Sciences Announces Expiration Of Waiting Period For CymaBay Tender Offer
Benzinga Newsdesk
-
Mar 11, 2024, 8:26AM
Friday, March 08, 2024
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
Vandana Singh
-
Mar 8, 2024, 10:02AM
Thursday, March 07, 2024
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Vandana Singh
-
Mar 7, 2024, 2:52PM
Wednesday, March 06, 2024
Gilead Sciences, Inc. Announces New Data From Three Studies Evaluating The Efficacy And Safety Profile Of Biktarvy, Demonstrating High Rates Of Viral Suppression In People With HIV And Comorbidities
Happy Mohamed
-
Mar 6, 2024, 4:47PM
Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy
Vandana Singh
-
Mar 6, 2024, 4:30PM
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
Vandana Singh
-
Mar 6, 2024, 4:21PM
Gilead and Merck Announce Phase 2 Data Showing An Investigational Oral Once-Weekly Combination Regimen Of Islatravir And Lenacapavir Maintained Viral Suppression At Week 24
Benzinga Newsdesk
-
Mar 6, 2024, 10:26AM
Gilead and Merus Announce Collaboration To Discover Novel Antibody-Based Trispecific T-Cell Engagers; Merus To Receive Upfront Cash Payment Of $56M For Initial Targets And Equity Investment By Gilead Of $25M in Merus Common Shares, Merus Is Also Eligible to Receive Up to $1.5B
Benzinga Newsdesk
-
Mar 6, 2024, 8:05AM
Tuesday, March 05, 2024
Gilead Sciences, Inc. Announces New Real-World Data Further Support The Use Of Veklury For People Hospitalized With COVID-19
Benzinga Newsdesk
-
Mar 5, 2024, 4:42PM
Gilead Highlights Presentation Of Data On HIV Treatment Research
Benzinga Newsdesk
-
Mar 5, 2024, 4:33PM
Monday, March 04, 2024
Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges
Vandana Singh
-
Mar 4, 2024, 11:39AM
Wells Fargo Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $77
Benzinga Newsdesk
-
Mar 4, 2024, 8:11AM
Monday, February 26, 2024
Gilead Sciences Says FDA Approves Expanded Indication For Biktarvy To Treat People With HIV With Suppressed Viral Loads, Pre-existing Resistance
Benzinga Newsdesk
-
Feb 26, 2024, 4:15PM
Gilead To Present Late-Breaking Data And Real-World Evidence Highlighting Innovative Antiviral Portfolio And Research Pipeline At CROI 2024
Benzinga Newsdesk
-
Feb 26, 2024, 8:38AM
Friday, February 23, 2024
$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today
Benzinga Insights
-
Feb 23, 2024, 10:00AM
Thursday, February 22, 2024
Truist Securities Downgrades Gilead Sciences to Hold, Lowers Price Target to $82
Benzinga Newsdesk
-
Feb 22, 2024, 7:29AM
Tuesday, February 20, 2024
RedHill's Published Data Shows That Opaganib Protects Against Radiation-Induced Lung Inflammation And Fibrosis
Benzinga Newsdesk
-
Feb 20, 2024, 9:07AM
Friday, February 16, 2024
Why Is Gilead Sciences Stock Trading Lower Today?
Vandana Singh
-
Feb 16, 2024, 12:50PM
Wednesday, February 14, 2024
RBC Capital Maintains Sector Perform on Gilead Sciences, Lowers Price Target to $75
Benzinga Newsdesk
-
Feb 14, 2024, 10:19AM
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Avi Kapoor
-
Feb 14, 2024, 6:54AM
Tuesday, February 13, 2024
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
Vandana Singh
-
Feb 13, 2024, 2:05PM
Monday, February 12, 2024
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
Avi Kapoor
-
Feb 12, 2024, 12:30PM
Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics
Benzinga Insights
-
Feb 12, 2024, 10:10AM
Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B
Vandana Singh
-
Feb 12, 2024, 9:22AM
Oppenheimer Maintains Outperform on Gilead Sciences, Lowers Price Target to $105
Benzinga Newsdesk
-
Feb 12, 2024, 8:40AM
Gilead Sciences Expands Liver Portfolio With Acquisition Of CymaBay Therapeutics For $32.50/Share Or A Total Equity Value Of $4.3B
Benzinga Newsdesk
-
Feb 12, 2024, 8:31AM
Friday, February 09, 2024
Top 5 Health Care Stocks That Are Preparing To Pump In February
Avi Kapoor
-
Feb 9, 2024, 8:35AM
Wednesday, February 07, 2024
Cantor Fitzgerald Maintains Neutral on Gilead Sciences, Lowers Price Target to $78
Benzinga Newsdesk
-
Feb 7, 2024, 1:43PM
S&P 500 Flirts With 5,000 As Magnificent 7 Tops $13 Trillion, NYCB Sinks: What's Driving Markets Wednesday?
Piero Cingari
-
Feb 7, 2024, 1:40PM
RBC Capital Maintains Sector Perform on Gilead Sciences, Lowers Price Target to $76
Benzinga Newsdesk
-
Feb 7, 2024, 12:08PM
Gilead Sciences shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS results and issued FY24 revenue guidance below estimates.
Benzinga Newsdesk
-
Feb 7, 2024, 10:27AM
Wells Fargo Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $84
Benzinga Newsdesk
-
Feb 7, 2024, 10:24AM
Gilead Sciences Says Reviewing Safety Of Magrolimab Across All Ongoing Solid Tumor Trials And Will Provide Update On This Assessment As Soon As Possible
Benzinga Newsdesk
-
Feb 7, 2024, 10:16AM
Gilead Sciences Says Magrolimab In Combination With Venetoclax Plus Azacitidine Demonstrated Futility And An Increased Risk Of Death In Patients With AML; Will Not Pursue Further Development Of Magrolimab In Hematologic Cancers
Benzinga Newsdesk
-
Feb 7, 2024, 10:16AM
Gilead Statement On Discontinuation Of Phase 3 Enhance-3 Study In AML; FDA Places Full Clinical Hold On All Magrolimab AML And MDS Studies, Including Expanded Access Programs
Benzinga Newsdesk
-
Feb 7, 2024, 10:15AM
$1000 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today
Benzinga Insights
-
Feb 7, 2024, 10:00AM
Tuesday, February 06, 2024
Why Gilead Sciences Stock Is Trading Lower After The Bell
Adam Eckert
-
Feb 6, 2024, 5:28PM
Gilead Sciences shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS results and issued FY24 revenue guidance below estimates.
Benzinga Newsdesk
-
Feb 6, 2024, 4:33PM
Gilead Sciences Sees FY24 Adj. EPS $6.85-$7.25 Vs $7.21 Est.; Revenue $27.1B-$27.5B Vs $27.663B Est.
Benzinga Newsdesk
-
Feb 6, 2024, 4:32PM
Gilead Sciences Announces Increase In First Quarter 2024 Dividend From $0.75 To $0.77 Per Share
Benzinga Newsdesk
-
Feb 6, 2024, 4:25PM
Gilead Sciences Q4 2023 Adj EPS $1.72 Misses $1.76 Estimate, Sales $7.10B Inline
Benzinga Newsdesk
-
Feb 6, 2024, 4:03PM
Tech Slides, Chinese Stocks Rebound, New York Community Bancorp Tumbles: What's Driving Markets Tuesday?
Piero Cingari
-
Feb 6, 2024, 2:24PM
Earnings Scheduled For February 6, 2024
Benzinga Insights
-
Feb 6, 2024, 5:42AM
Monday, February 05, 2024
Preview: Gilead Sciences's Earnings
Benzinga Insights
-
Feb 5, 2024, 9:01AM
Wednesday, January 31, 2024
A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?
Meg Flippin
-
Sponsored
Tuesday, January 30, 2024
Kite, A Gilead Company, Received FDA Approval Of Manufacturing Process Change Resulting In Reduced Median Turnaround Time For Yescarta CAR T-cell Therapy
Benzinga Newsdesk
-
Jan 30, 2024, 9:10AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch